Processa Pharmaceuticals In-Licenses Ocuphire’s Anticancer Agent
Processa Pharmaceuticals Inc (NASDAQ:PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ:OCUP) to in-license RX-3117. RX-3117 is an oral anticancer…
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.